Completed

Hepatic Resection Followed by Concurrent Adjuvant Portal Vein Infusion of Fluorodeoxyuridine and Systemic 5-Fluorouracil and Folinic Acid for Metastatic Colorectal Carcinoma

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

floxuridine

+ fluorouracil

+ leucovorin calcium

DrugProcedure
Who is being recruted

Colonic Diseases+14

+ Digestive System Diseases

+ Digestive System Neoplasms

From 18 to 70 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 2
Interventional
Study Start: September 1994
See protocol details

Summary

Principal SponsorCity of Hope Medical Center
Last updated: April 11, 2017
Sourced from a government-validated database.Claim as a partner

Study start date: September 1, 1994

Actual date on which the first participant was enrolled.

OBJECTIVES: Evaluate the efficacy of hepatic resection followed by portal vein infusion of floxuridine plus systemic fluorouracil/leucovorin calcium in patients with metastatic colorectal cancer. Study the toxic effects of adjuvant chemotherapy following hepatic resection. Evaluate mRNA expression of enzymes that may be important to the cytotoxicity of fluoropyrimidines in tumor cells, including thymidylate synthase, ribonucleotide reductase, and folylglutamyl synthetase, by polymerase chain reaction and immunohistochemistry. OUTLINE: Following resection of the liver and all extrahepatic colorectal cancer, patients receive floxuridine via portal vein infusion from days 1-14. Systemic chemotherapy consists of leucovorin calcium on days 8-14 and fluorouracil on days 9-13. Courses repeat every 4 weeks for a total of 12 weeks. If biopsy-proven metastatic disease develops, treatment may be stopped at the investigator's discretion. Continuation of regional therapy should be considered for extrahepatic failure. No concurrent radiotherapy is permitted. Patients are followed every 3 months for 3 years, then every 6 months for survival. PROJECTED ACCRUAL: It is expected that 50 patients will be entered over approximately 5 years.

NCT00002842
Principal SponsorCity of Hope Medical Center
Last updated: April 11, 2017
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

49 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 70 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Colonic DiseasesDigestive System DiseasesDigestive System NeoplasmsGastrointestinal DiseasesGastrointestinal NeoplasmsIntestinal DiseasesIntestinal NeoplasmsNeoplasmsNeoplasms by SiteNeoplastic ProcessesPathologic ProcessesRectal DiseasesPathological Conditions, Signs and SymptomsColonic NeoplasmsNeoplasm MetastasisRectal NeoplasmsColorectal Neoplasms

Criteria

DISEASE CHARACTERISTICS: Histologically confirmed colorectal carcinoma or radiologically confirmed colorectal carcinoma in a synchronous metastasis Intrahepatic metastases required No more than 15 metastases involving no more than 60% of functioning liver No extrahepatic disease unless: Resectable anastomotic or locally recurrent tumor Resectable mesenteric lymph node involvement in patients undergoing initial resection of primary colorectal carcinoma Disease extension from liver metastasis amenable to en bloc resection (e.g., diaphragm wall, kidney, abdominal wall) No biopsy-proven chronic active hepatitis PATIENT CHARACTERISTICS: Age: Physiologic 18 to 70 Performance status: Karnofsky 60%-100% Hematopoietic: AGC at least 1,500 Platelets at least 100,000 Hepatic: Bilirubin no greater than 2.0 mg/dL (unless reversibly obstructed by metastasis) Renal: Creatinine no greater than 2.0 mg/dL Other: No second malignancy within 5 years except adequately treated: Nonmelanomatous skin cancer In situ bladder cancer In situ cervical cancer No pregnant women PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Prior mitomycin or nitrosoureas allowed Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to the liver At least 3 weeks since radiotherapy and recovered Prior pelvic radiotherapy allowed No planned concurrent radiotherapy Surgery: Not specified

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Patients receive floxuridine via portal vein infusion from days 1-14. Systemic chemotherapy consists of leucovorin calcium on days 8-14 and fluorouracil on days 9-13. Courses repeat every 4 weeks for a total of 12 weeks

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

City of Hope Comprehensive Cancer Center

Duarte, United StatesOpen City of Hope Comprehensive Cancer Center in Google Maps
CompletedOne Study Center